Optical clearing of vaginal tissues, ex vivo, for minimally invasive laser treatment of female stress urinary incontinence.
Chun-Hung Chang, Erinn M Myers, Michael J Kennelly...
https://pubmed.ncbi.nlm.nih.gov/28301637/Actively Recruiting
Led by University of California, Irvine · Updated on 2026-02-18
50
Participants Needed
1
Research Sites
8 weeks
Total Duration
Genitourinary Syndrome of Menopause GSM happens when estrogen levels drop as women near menopause, causing symptoms like vaginal dryness, burning, less lubrication, painful intercourse, and urinary issues such as urgency and frequency. This syndrome affects quality of life, and while vaginal estrogen is commonly used for treatment, some women cannot use hormones due to health risks like breast cancer or blood clots. This trial studies the use of vaginal CO2 laser therapy as a non-hormonal treatment option, using advanced imaging technology to observe vaginal tissue changes during menopause and after treatment. Participants will be randomly assigned to either receive vaginal laser therapy using a fractional CO2 laser or a sham treatment where the laser probe is placed but no energy is delivered. The laser treatment involves specific energy settings adjusted for comfort and is given in three sessions. The sham group undergoes the same procedure without actual laser pulses. The study uses a non-invasive vaginal probe with optical coherence tomographyangiographyelastography OCTOCTAOCE imaging to measure vaginal tissue thickness and blood vessel density. Throughout the study, participants will have monthly measurements during the first three months and follow-up visits every three months for a year. These visits include imaging of the vaginal canal, questionnaires about symptoms and quality of life, physical exams, and vaginal swabs to assess the microbiome. Researchers will monitor changes in vaginal epithelial thickness and blood vessel density, as well as symptom improvement and overall health impact, to evaluate the effects of laser treatment compared to sham therapy.
CONDITIONS
Vaginal Changes After CO2 Laser
K
Karla LORENTE, MD
N
Nicole Wakida
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, Irvine
Lead Sponsor
Alma Lasers
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | CO2 Vaginal Laser | Sham (No Laser) |
|---|---|---|
| What it is | A fractional CO2 laser procedure performed inside the vagina to deliver thermal energy to the vaginal walls, aimed at treating symptoms related to genitourinary syndrome of menopause. | A sham (placebo-like) vaginal procedure in which instrumentation is applied but no active laser energy is delivered; designed to mimic the experience of treatment without the therapeutic effect. |
| Role in trial | Interventional arm, receiving active treatment intended to improve GSM symptoms and vaginal tissue health. | Control arm, receiving the sham procedure for comparison without therapeutic laser energy. |
| Primary use | Intended for the treatment of symptoms and tissue changes associated with genitourinary syndrome of menopause, including changes in vaginal epithelium and blood vessel density. | Serves as a placebo for comparison purposes and does not provide active treatment for GSM. |
| How it is given or performed | CO2 laser is administered inside the vaginal canal on a predetermined schedule, with procedures performed by clinicians in a medical setting. | A procedure that mimics the active arm in time and method but without applying any laser energy. |
| Evidence status | Evidence from multiple randomized controlled trials in postmenopausal women shows mixed results for improvement in GSM symptoms and vaginal tissue changes. While some studies report benefit, at least one high-quality trial found no significant symptom improvement over sham at 12 months. | Sham procedures do not deliver active therapy and serve as placebo comparators in clinical trials. Symptom improvements in the sham arm are attributed to the placebo effect and study participation. |
| Important limitations | Long-term safety and effectiveness are unknown. Some guidelines and expert groups highlight gaps in evidence, and energy-based therapies are not currently considered standard-of-care for GSM. Not all studies include comparisons with established treatments (such as local estrogen therapy). | Sham intervention provides no therapeutic benefit for GSM and is only used within clinical trials for comparison; it does not represent a real-world care option. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants receive either CO2 vaginal laser therapy or a sham procedure once a month for three months while undergoing vaginal measurements and assessments using the OCT device.
Monthly visits for 3 months
Duration - 1 year
Participants continue with follow-up visits every 3 months for 1 year to monitor vaginal epithelial thickness, blood vessel density, and other health assessments using the OCT device and questionnaires.
Visits every 3 months for 1 year
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Chun-Hung Chang, Erinn M Myers, Michael J Kennelly...
https://pubmed.ncbi.nlm.nih.gov/28301637/Saijun Qiu, Afiba Arthur, Yuchen Jiang...
https://pubmed.ncbi.nlm.nih.gov/37946874/Yona Tadir, Adrian Gaspar, Ahinoam Lev-Sagie...
https://pubmed.ncbi.nlm.nih.gov/28220946/S Athanasiou, E Pitsouni, S Antonopoulou...
https://pubmed.ncbi.nlm.nih.gov/27558459/Fiona G Li, Sarah Maheux-Lacroix, Rebecca Deans...
https://pubmed.ncbi.nlm.nih.gov/34636862/Jason Gandhi, Andrew Chen, Gautam Dagur...
https://pubmed.ncbi.nlm.nih.gov/27472999/Yan Li, Neha T Sudol, Yusi Miao...
https://pubmed.ncbi.nlm.nih.gov/30058722/Nanette Santoro, Janne Komi
https://pubmed.ncbi.nlm.nih.gov/19493278/Eleni Pitsouni, Themos Grigoriadis, Matthew E Falagas...
https://pubmed.ncbi.nlm.nih.gov/28778337/Chantal M Diedrich, Arnoud W Kastelein, Filippo M Verri...
https://pubmed.ncbi.nlm.nih.gov/30947367/University of California, Irvine
Lead Sponsor
Alma Lasers
Collaborating Sponsor